Allergan (AGN) Slips Lower on FDA Generic Restasis Discussion
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/28/2026
- S&P 500 ends lower; chips tumble and Moderna rallies
- SpaceX weighs Starlink mobile service to US consumers, FT reports
- U.S. chip stocks retreat after Apple price hikes stoke fears over AI trade
- Morgan Stanley flags Fed hike risk if unemployment drops below 4%
- UBS trims AI portfolio exposure to semis and hardware after recent rally
Wells Fargo Downgrades Allergen (AGN) to Market Perform
June 25, 2013 6:48 AM EDTWells Fargo downgraded Allergen (NYSE: AGN) from Outperform to Market Perform following generic Restasis documents from the FDA.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $81.99 yesterday, with a 52 week range of $81.28-$116.45.... More
Citi Downgrades Allergen (AGN) to Neutral
June 24, 2013 12:38 PM EDTCiti downgraded Allergen (NYSE: AGN) from Buy to Neutral.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $92.70 yesterday, with a 52 week range of $81.28-$116.45.... More
SunTrust Robinson Humphrey Downgrades Allergen (AGN) to Neutral
June 24, 2013 8:10 AM EDTSunTrust Robinson Humphrey downgraded Allergen (NYSE: AGN) from Buy to Neutral.
For an analyst ratings summary and ratings history on Allergen click here. For more ratings news on Allergen click here.
Shares of Allergen closed at $92.70 yesterday, with a 52 week range of $81.28-$116.45.... More
Deutsche Bank Downgrades Allergen (AGN) to Hold; Sees 'Overhang' from Generic Restasis
June 24, 2013 7:10 AM EDTDeutsche Bank downgraded Allergen (NYSE: AGN) from Buy to Hold with a price target of $98.00 (from $113.00) after the FDA issued draft guidance for a non-clinical study pathway for generics to Restasis, the company's 2nd largest drug (~14% of revs) with 2015E sales of $1B+.
... More
Leerink Swann Downgrades Allergen (AGN) to Market Perform on Prospect of Restasis Generics
June 24, 2013 7:07 AM EDTLeerink Swann downgraded Allergen (NYSE: AGN) from Outperform to Market Perform with a price target of $102.00 (from $113-$114).
"We are downgrading AGN from Outperform to Market Perform following the release of surprisingly straightforward draft guidance from the FDA for Restasis generics (dry eye)," analyst... More
